JP2023521631A5 - - Google Patents

Info

Publication number
JP2023521631A5
JP2023521631A5 JP2022559959A JP2022559959A JP2023521631A5 JP 2023521631 A5 JP2023521631 A5 JP 2023521631A5 JP 2022559959 A JP2022559959 A JP 2022559959A JP 2022559959 A JP2022559959 A JP 2022559959A JP 2023521631 A5 JP2023521631 A5 JP 2023521631A5
Authority
JP
Japan
Prior art keywords
mixture
formula
compound
crystal
diffraction angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559959A
Other languages
English (en)
Japanese (ja)
Other versions
JP7660135B2 (ja
JP2023521631A (ja
Filing date
Publication date
Priority claimed from GBGB2005114.0A external-priority patent/GB202005114D0/en
Application filed filed Critical
Publication of JP2023521631A publication Critical patent/JP2023521631A/ja
Publication of JP2023521631A5 publication Critical patent/JP2023521631A5/ja
Application granted granted Critical
Publication of JP7660135B2 publication Critical patent/JP7660135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559959A 2020-04-07 2021-04-06 Tyk2阻害剤の結晶形態 Active JP7660135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2005114.0A GB202005114D0 (en) 2020-04-07 2020-04-07 Crystalline Forms of a Pharmaceutical Compound
GB2005114.0 2020-04-07
PCT/EP2021/058864 WO2021204762A1 (en) 2020-04-07 2021-04-06 Crystalline forms of a tyk2 inhibitor

Publications (3)

Publication Number Publication Date
JP2023521631A JP2023521631A (ja) 2023-05-25
JP2023521631A5 true JP2023521631A5 (cg-RX-API-DMAC7.html) 2024-04-01
JP7660135B2 JP7660135B2 (ja) 2025-04-10

Family

ID=70768933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559959A Active JP7660135B2 (ja) 2020-04-07 2021-04-06 Tyk2阻害剤の結晶形態

Country Status (11)

Country Link
US (2) US12545652B2 (cg-RX-API-DMAC7.html)
EP (1) EP4132649A1 (cg-RX-API-DMAC7.html)
JP (1) JP7660135B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220164751A (cg-RX-API-DMAC7.html)
CN (1) CN115515683B (cg-RX-API-DMAC7.html)
BR (1) BR112022016359A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167172A1 (cg-RX-API-DMAC7.html)
GB (1) GB202005114D0 (cg-RX-API-DMAC7.html)
IL (1) IL296989A (cg-RX-API-DMAC7.html)
MX (1) MX2022011593A (cg-RX-API-DMAC7.html)
WO (1) WO2021204762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
JP2025510826A (ja) * 2022-03-25 2025-04-15 武田薬品工業株式会社 Tyk2阻害剤の固体形態及び使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG11201401342VA (en) 2011-10-12 2014-09-26 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
BR112016004723B1 (pt) * 2013-09-03 2022-08-30 Sareum Limited Compostos de pirrolidina ou morfolina e composição contendo os mesmos
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
KR101391132B1 (ko) 결정형 미노사이클린 염기 및 이의 제조방법
JP2022176979A5 (cg-RX-API-DMAC7.html)
JP2019104760A (ja) ベンズイミダゾール誘導体の新規結晶形及びその製造方法
JP2018528199A5 (cg-RX-API-DMAC7.html)
KR102266680B1 (ko) 벨리노스테트의 다형태 및 이의 제조 방법
JP2024521412A5 (cg-RX-API-DMAC7.html)
EP1812397A1 (en) Process of making crystalline aripiprazole
WO2018210302A1 (zh) 一种苯并呋喃类衍生物游离碱的晶型及制备方法
TWI727517B (zh) 貝前列素-314d晶體及其製備方法
JP5826371B2 (ja) ペメトレキセド塩の製造方法
CN115572298B (zh) 一种核苷类似物及其盐的晶型、制备方法和应用
CA2806820A1 (en) N-methylformamide solvate of dasatinib
JP2025517714A (ja) トリアジンジオン系誘導体の結晶形及び調製方法
CN107531744A (zh) 一种奥贝胆酸的新结晶形式及其制备方法
CN110536888B (zh) 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
WO2017092702A1 (zh) 奥贝胆酸晶型ⅱ及其制备方法和用途
WO2014195977A2 (en) Novel polymorphs of vismodegib
CN101925602B (zh) 基本上不含溶剂的阿巴卡韦的结晶形式
JP2025031139A (ja) ジヒドロスフィンゴミエリンの結晶、及び、その製造方法、並びに、医薬組成物
JP4655930B2 (ja) キノリンカルボン酸誘導体溶媒和物の結晶
RU2022120823A (ru) Кристаллические формы ингибитора tyk2
CN116096369A (zh) 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
JP6944372B2 (ja) ピペラジン化合物の新規結晶
JP6577938B2 (ja) セフジトレンピボキシルの新規結晶形態およびその製造方法
KR20150127996A (ko) 실로도신 감마형 결정의 제조방법